Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA.
Vet Clin Pathol. 2022 Jun;51(2):216-224. doi: 10.1111/vcp.13089. Epub 2022 Mar 10.
Thrombocytopenia has been associated with some neoplastic processes, including hematologic neoplasia. There is no information regarding specific changes in platelet measurands in dogs with hematologic neoplasia compared with healthy dogs. The objectives of our study were to establish RIs, evaluate platelet measurands in dogs with hematologic neoplasia, and compare these measurands in patients with hematologic malignancies with or without thrombocytopenia.
This was a retrospective study. Platelet measurands were determined using the ADVIA 120 Hematology analyzer when a CBC was performed and included the platelet count, MPV, platelet distribution width (PDW), plateletcrit (PCT), mean platelet component (MPC), platelet component distribution width (PCDW), mean platelet mass (MPM), platelet mass distribution width (PMDW), and number of large platelets. Reference intervals were determined retrospectively using data from 129 healthy dogs. Patients with hematologic neoplasia (n = 50) were identified through retrospective evaluation of medical records from the Auburn University Veterinary Teaching Hospital and separated into thrombocytopenic (n = 20) and nonthrombocytopenic groups (n = 30).
Platelet count and PCT were significantly higher in older healthy dogs compared with younger dogs. Significant differences were identified when comparing healthy dogs with those with hematologic neoplasia without thrombocytopenia for PDW, PCDW, PMDW, and the number of large platelets, indicating the presence of more heterogeneous platelets. Thrombocytopenic dogs with hematologic neoplasia had significantly decreased MPCs and increased MPVs, MPMs, and PCDWs compared with nonthrombocytopenic dogs with neoplasia.
Dogs with hematologic neoplasia had more heterogeneous platelets, whereas thrombocytopenic patients with neoplasia had more activated platelets.
血小板减少症与一些肿瘤过程有关，包括血液系统肿瘤。目前尚无关于与健康犬相比，血液系统肿瘤犬的血小板测量值有何具体变化的信息。我们研究的目的是建立 RI，评估血液系统肿瘤犬的血小板测量值，并比较伴有或不伴有血小板减少症的血液系统恶性肿瘤患者的这些测量值。
这是一项回顾性研究。当进行全血细胞计数（CBC）时，使用 ADVIA 120 血液学分析仪测定血小板测量值，包括血小板计数、MPV、血小板分布宽度（PDW）、血小板比容（PCT）、平均血小板成分（MPC）、血小板成分分布宽度（PCDW）、平均血小板质量（MPM）、血小板质量分布宽度（PMDW）和大血小板数量。使用来自 129 只健康犬的数据，通过回顾性评估奥本大学兽医教学医院的病历，确定了血液系统肿瘤患者（n=50）的参考区间，并将其分为血小板减少组（n=20）和非血小板减少组（n=30）。
与年轻犬相比，老年健康犬的血小板计数和 PCT 明显更高。与无血小板减少的血液系统肿瘤健康犬相比，血小板减少的血液系统肿瘤犬的 PDW、PCDW、PMDW 和大血小板数量存在显著差异，表明存在更多异质性血小板。与无肿瘤的非血小板减少性血液病犬相比，有血液病的血小板减少性犬的 MPC 明显降低，MPV、MPM 和 PCDW 明显升高。
患有血液系统肿瘤的犬的血小板更异质，而患有血液系统肿瘤的血小板减少的患者的血小板更活跃。
